0001193125-20-176540.txt : 20200623 0001193125-20-176540.hdr.sgml : 20200623 20200623162007 ACCESSION NUMBER: 0001193125-20-176540 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200623 DATE AS OF CHANGE: 20200623 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Evofem Biosciences, Inc. CENTRAL INDEX KEY: 0001618835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208527075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88576 FILM NUMBER: 20982106 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 550-1900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Neothetics, Inc. DATE OF NAME CHANGE: 20140905 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Link Fund Solutions Ltd CENTRAL INDEX KEY: 0001792424 IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 65 GRESHAM STREET CITY: LONDON STATE: X0 ZIP: EC2V 7NQ BUSINESS PHONE: 44 (0)20 7954 9710 MAIL ADDRESS: STREET 1: 65 GRESHAM STREET CITY: LONDON STATE: X0 ZIP: EC2V 7NQ SC 13G/A 1 d938512dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No. _1__)*

 

 

Evofem Biosciences Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

30048L104

(CUSIP Number)

June 4, 2020

(Date of Event which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐Rule 13d-1(b)

☒Rule 13d-1(c)

☐Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

SCHEDULE 13G

 

CUSIP No.    30048L104  

 

  1   

Names of Reporting Persons

 

Link Fund Solutions Limited

  2  

Check the appropriate box if a member of a Group (see instructions)

(a)  ☐        (b)  ☐

 

  3  

SEC Use Only

 

  4  

Citizenship or Place of Organization

 

United Kingdom

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

    5    

Sole Voting Power

 

0

   6   

Shared Voting Power

 

0

   7   

Sole Dispositive Power

 

0

   8   

Shared Dispositive Power

 

0

  9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0

10  

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

 

☐

11  

Percent of class represented by amount in Row (9)

 

0%

12  

Type of Reporting Person (See Instructions)

 

CO

 

Page 2 of 5

Item 1.

 

(a)

Name of Issuer: Evofem Biosciences Inc. (the “Issuer”)

 

(b)

Address of Issuer’s Principal Executive Offices:

12400 High Bluff Drive, Suite 600

San Diego, CA 92130

U.S.A.

 

Item 2.

 

(a)

Name of Person Filing: Link Fund Solutions Limited (“LFS”)

 

(b)

Address of Principal Business Office or, if None, Residence: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

 

(c)

Citizenship: United Kingdom

 

(d)

Title and Class of Securities: Common Stock, par value $0.0001 per share

 

(e)

CUSIP No.: 30048L104

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

   

☐

      Broker or dealer registered under Section 15 of the Act;

(b)

   

☐

      Bank as defined in Section 3(a)(6) of the Act;

(c)

   

☐

      Insurance company as defined in Section 3(a)(19) of the Act;

(d)

   

☐

      Investment company registered under Section 8 of the Investment Company Act of 1940;

(e)

   

☐

      An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)

   

☐

      An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g)

   

☐

      A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)

   

☐

      A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

   

☐

      A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j)

   

☐

      A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

(k)

   

☐

      Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

 

Page 3 of 5

Item 4.

Ownership

The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page and is incorporated herein by reference.

The percentage set forth in Row 11 of this Schedule 13G (Amendment No. 1) is calculated based upon 49,722,668 shares of Common Stock issued and outstanding as of April 30, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, filed with the Securities and Exchange Commission on May 6, 2020.

 

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

 

Item 6.

Ownership of more than Five Percent on Behalf of Another Person. Not applicable.

 

Item 7.

Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. Not applicable.

 

Item 8.

Identification and classification of members of the group. Not applicable.

 

Item 9.

Notice of Dissolution of Group. Not applicable.

 

Item 10.

Certifications.

 

Page 4 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: 23 June 2020

LINK FUND SOLUTIONS LIMITED

 

By:

  

/s/ Nigel Boyling

    Name: Nigel Boyling
    Title: Director

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

 

Page 5 of 5